Loading...

Lindsay Ann Renfro

TitleAssociate Professor of Research Preventive Medicine
InstitutionUniversity of Southern California
DepartmentPreventive Medicine
Address2001 N. Soto Street
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kimani PK, Todd S, Renfro L, Stallard N. Point estimation following two-stage adaptive threshold enrichment clinical trials. Stat Med. 2018 May 31. PMID: 29855066.
      View in: PubMed
    2. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro L, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018 03 29; 378(13):1177-1188. PMID: 29590544.
      View in: PubMed
    3. Sjoquist KM, Renfro L, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2017 Dec 18. PMID: 29267900.
      View in: PubMed
    4. Grothey A, Strosberg JR, Renfro L, Hurwitz HI, Marshall JL, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clin Cancer Res. 2018 Jan 15; 24(2):316-325. PMID: 29084918.
      View in: PubMed
    5. Renfro L, Mandrekar SJ. Definitions and statistical properties of master protocols for personalized medicine in oncology. J Biopharm Stat. 2018; 28(2):217-228. PMID: 28877008.
      View in: PubMed
    6. Jones JC, Renfro L, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017 Aug 10; 35(23):2624-2630. PMID: 28486044.
      View in: PubMed
    7. Lynn PB, Renfro L, Carrero XW, Shi Q, Strombom PL, Chow O, Garcia-Aguilar J. Anorectal Function and Quality of Life in Patients With Early Stage Rectal Cancer Treated With Chemoradiation and Local Excision. Dis Colon Rectum. 2017 May; 60(5):459-468. PMID: 28383445.
      View in: PubMed
    8. Renfro L, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. J Clin Oncol. 2017 Jun 10; 35(17):1929-1937. PMID: 28414610.
      View in: PubMed
    9. Renfro L, Sargent DJ. Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. Chin Clin Oncol. 2016 Dec; 5(6):80. PMID: 28061544.
      View in: PubMed
    10. Renfro L, Shi Q, Sargent DJ. Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges. J Clin Oncol. 2016 Nov 10; 34(32):3949-3950. PMID: 27551133.
      View in: PubMed
    11. Renfro L, Zhang N, Lopatin M, Chao C, Alberts SR. Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer. Clin Colorectal Cancer. 2017 03; 16(1):23-30. PMID: 27600983.
      View in: PubMed
    12. Papamichael D, Renfro L, Matthaiou C, Yothers G, Saltz L, Guthrie KA, Van Cutsem E, Schmoll HJ, Labianca R, André T, O'Connell M, Alberts SR, Haller DG, Kountourakis P, Sargent DJ. Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. J Geriatr Oncol. 2016 Nov; 7(6):422-429. PMID: 27468630.
      View in: PubMed
    13. Renfro L, An MW, Mandrekar SJ. Precision oncology: A new era of cancer clinical trials. Cancer Lett. 2017 02 28; 387:121-126. PMID: 26987624.
      View in: PubMed
    14. Cheung WY, Renfro L, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol. 2016 Apr 10; 34(11):1182-9. PMID: 26858337; PMCID: PMC4933130 [Available on 12/10/16].
    15. Shah MA, Renfro L, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016 Mar 10; 34(8):843-53. PMID: 26811529; PMCID: PMC4872008 [Available on 12/10/16].
    16. Renfro L, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev. 2016 Feb; 43:74-82. PMID: 26827695; PMCID: PMC4737867 [Available on 02/01/17].
    17. Renfro L, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol. 2016 Jan 10; 34(2):144-50. PMID: 26503203.
      View in: PubMed
    18. Garcia-Aguilar J, Renfro L, Chow OS, Shi Q, Carrero XW, Lynn PB, Thomas CR, Chan E, Cataldo PA, Marcet JE, Medich DS, Johnson CS, Oommen SC, Wolff BG, Pigazzi A, McNevin SM, Pons RK, Bleday R. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015 Nov; 16(15):1537-1546. PMID: 26474521.
      View in: PubMed
    19. Foster NR, Renfro L, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. PMID: 26134227; PMCID: PMC4493926.
    20. Renfro L, Shang H, Sargent DJ. Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points. J Biopharm Stat. 2015; 25(4):857-77. PMID: 24905465; PMCID: PMC4270950.
    21. Renfro L, Grothey AM, Paul J, Floriani I, Bonnetain F, Niedzwiecki D, Yamanaka T, Souglakos I, Yothers G, Sargent DJ. Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting analysis dates for the IDEA collaboration. Forum Clin Oncol. 2014 Dec; 5(2):1-7. PMID: 26989447.
      View in: PubMed
    22. Alberts SR, Yu TM, Behrens RJ, Renfro L, Srivastava G, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim GP, Mazurczak MA, Hornberger J. Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics. 2014 Dec; 32(12):1231-43. PMID: 25154747; PMCID: PMC4244576.
    23. Renfro L, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ. ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Dec; 106(12). PMID: 25359867; PMCID: PMC4334801.
    24. Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ, Maizels N. MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. PLoS One. 2014; 9(10):e108483. PMID: 25310185; PMCID: PMC4195600.
    25. Renfro L, Shi Q, Xue Y, Li J, Shang H, Sargent DJ. Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints. Comput Stat Data Anal. 2014 Oct 01; 78:1-20. PMID: 25061255.
      View in: PubMed
    26. Lieu CH, Renfro L, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol. 2014 Sep 20; 32(27):2975-84. PMID: 25002720.
      View in: PubMed
    27. Shiovitz S, Bertagnolli MM, Renfro L, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014 Sep; 147(3):637-45. PMID: 24859205.
      View in: PubMed
    28. Sanoff HK, Renfro L, Poonnen P, Ambadwar P, Sargent DJ, Goldberg RM, McLeod H. Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer. PLoS One. 2014; 9(4):e94727. PMID: 24727911; PMCID: PMC3984266.
    29. Srivastava G, Renfro L, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, Mazurczak M, Lee M, Alberts SR. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014 May; 19(5):492-7. PMID: 24710310; PMCID: PMC4012966.
    30. Renfro L, Coughlin CM, Grothey AM, Sargent DJ. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chin Clin Oncol. 2014 Mar 01; 3(1). PMID: 25485277.
      View in: PubMed
    31. Renfro L, Coughlin CM, Grothey AM, Sargent DJ. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chin Clin Oncol. 2014 Mar; 3(1):3. PMID: 25842081.
      View in: PubMed
    32. Renfro L, Shi Q, Sargent DJ. Mining the ACCENT database: a review and update. Chin Clin Oncol. 2013 Jun; 2(2):18. PMID: 25841498; PMCID: PMC4407359.
    33. Shafi S, Renfro L, Barnes S, Rayan N, Gentilello LM, Fleming N, Ballard D. Chronic consequences of acute injuries: worse survival after discharge. J Trauma Acute Care Surg. 2012 Sep; 73(3):699-703. PMID: 22710768.
      View in: PubMed
    34. Renfro L, Shi Q, Sargent DJ, Carlin BP. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. Stat Med. 2012 Apr 13; 31(8):743-61. PMID: 22161275.
      View in: PubMed
    35. Renfro L, Carlin BP, Sargent DJ. Bayesian adaptive trial design for a newly validated surrogate endpoint. Biometrics. 2012 Mar; 68(1):258-67. PMID: 21838811; PMCID: PMC3218207.